黄素作为β-碳酸盐的天然抑制剂:机理性洞察力
Qiaochun Chen1, Zening Zhang2, Weiqi Qiu1
1Institute for Advanced Study, Shenzhen University, Shenzhen 518060, P. R. China.
Journal of agricultural and food chemistry
|November 6, 2025
概括
黄类化合物通过清除自由基和捕获化物来抑制有害的食源β-碳醇蛋白. 这些双重机制减少了有毒化合物的形成,为食品安全应用提供了潜力.
科学领域:
- 食品化学 食品化学
- 毒理学 毒理学 毒理学
- 自然产品 自然产品
背景情况:
- 通过食物传播的β-卡博林异环胺,如哈曼和诺哈曼,是食品加工过程中形成的有毒化合物.
- 黄类药物对这些有毒物质的精确抑制机制尚未完全理解.
研究的目的:
- 阐明黄类药物的抑制机制对食品传播β-卡博林的形成.
- 为了将黄胺结构与其抑制功效相关联.
主要方法:
- 使用了结构-活动和相关性分析.
- 模型系统和大豆盐水被用于研究抑制作用.
- 超高性能液体染色学与并联质谱学 (UPLC-MS/MS) 结合,确定了关键的引证.
主要成果:
- 黄类抑制作用在13.36%至86.98%之间,与基基和抗氧化能力有关.
- 激进的清理防止了四-β-卡博林 (THβCs) 氧化成β-卡博林.
- 黄类化合物与化物形成添加物,降低THβC和甲/乙甲水平.
- 确定了两个主要的添加物 (三甲-甲-黄和黄-甲-黄).
结论:
- 黄类药物通过激素清除和阿尔德捕获机制来抑制β-卡博林的形成.
- 有效性可能受到现有的有毒物质和食物矩阵中的黄类溶解度的限制.
- 黄类药物显示出控制食物中传递的有毒物质的前景.
更多相关视频
相关概念视频
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
896
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
896
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.7K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.7K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.0K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.4K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.4K


